ArticleChild's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery2025
Lymphoid enhancer-binding factor 1 (LEF1): a reliable immunohistochemical predictive marker for WNT-activated medulloblastoma.
Article in Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Biomarkers of Treatment Response in Paediatric Medulloblastoma.Diagnostics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo evaluate lymphoid enhancer-binding factor 1 (LEF1) as an immunohistochemical marker for WNT-activated medulloblastoma (WNT-MB). MATERIALS AND
methodsMedulloblastomas (MB) diagnosed between January 2022 and April 2024, that were molecularly grouped by gene expression profiling and in which LEF1 immunohistochemistry was available formed the study cohort.
resultsA of total 151 cases, comprising 40 (26.49%) WNT-activated, 45 (29.80%) SHH-activated, and 66 (43.71%) non-WNT/non-SHH (group 3: 21, group 4: 34, and NOS, i.e. overlapping between group 3 and group 4: 11) formed the study cohort. Age- range was 1-41 years (median: 9 years; interquartile- range: 5-17 years), 118 (78.15%) patients were ≤ 18 years of age, and 33 (21.85%) patients had > 18 years age. LEF1 immunostaining was diffuse (≥ 50% tumour cells) in 32 cases, focal (1-49% tumour cells) in 11 cases, and negative in 108 cases. Diffuse LEF1 staining was observed only in WNT-MB. Focal LEF1 staining was observed in 20% (8/40) of WNT-MB and 6.67% (3/45) of SHH-activated MBs. All 66 non-WNT/non-SHH MB were negative for LEF1. Diffuse (> 50%) LEF1 immunostaining had 100% positive predictive value, 100% specificity and 80% sensitivity for detecting WNT-MB.
conclusionDiffuse LEF1 immunostaining is a reliable and faster method for identifying WNT-activated molecular group of MB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.